PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,126.00
Bid: 12,126.00
Ask: 12,128.00
Change: -40.00 (-0.33%)
Spread: 2.00 (0.016%)
Open: 12,186.00
High: 12,198.00
Low: 12,114.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: FTSE 100 flat, peers and pound up before US data

Thu, 10th Aug 2023 11:59

(Alliance News) - London's FTSE 100 underwhelmed on Thursday, as a slew of its heavyweights went ex-dividend, though blue-chip equities in mainland Europe were higher, showing no signs of pre-US inflation data angst and overlooking an acceleration in tensions between the world's two largest economies.

The FTSE 100 index went into Thursday afternoon just 3.58 points lower at 7,583.72. The FTSE 250 was down just 4.05 points at 18,933.15, and the AIM All-Share was down 1.69 points, 0.2%, at 756.29.

The Cboe UK 100 was up 0.1% at 756.47, the Cboe UK 250 was up 0.3% at 16,637.94, and the Cboe Small Companies was up 0.1% at 13,610.77.

In European equities on Thursday, the CAC 40 in Paris was up 0.8%, while the DAX 40 in Frankfurt was 0.3% higher.

Ahead of the US inflation data reported at 1330 BST, the dollar was largely weaker.

The pound was quoted at USD1.2772 early Thursday afternoon in London, climbing from USD1.2717 at the London equities close on Wednesday. The euro traded at USD1.1027, up from USD1.0977. Against the yen, the dollar rose to JPY143.80, from JPY143.60.

According to FXStreet cited consensus, the US annual inflation rate is expected to heat up to 3.3%, from 3.0% in June. The core inflation rate, which excludes food and energy, is expected to remain at 4.8%.

"The last reading provided a positive surprise as it undershot expectations for the first time in a long time. A repeat could revive a flagging equity rally, but a negative shock could accelerate recent selling," AJ Bell analyst Russ Mould commented.

A hotter-than-expected reading could mean the Federal Reserve continues with its hiking cycle.

Oanda analyst Craig Erlam commented: "It will take something big for the Fed to consider hiking again you would think, having shifted to a more gradual approach in recent months."

In London, share price falls of 1.2% and 1.3% for lenders HSBC and NatWest, 1.1% for drugmaker AstraZeneca and 3.0% for miner Rio Tinto hurt the FTSE 100. The stocks went ex-dividend, meaning new buyers do not qualify for the latest payouts.

Spirax-Sarco fell 5.0%, sitting at the bottom of the large-cap index.

The Cheltenham, England-based thermal energy management and pumping company said pretax profit fell 18% to GBP114.0 million, from GBP138.5 million a year ago.

The firm reported revenue of GBP850.8 million in the first half of 2023, up 13% from GBP750.1 million the year prior.

Spirax warned destocking in Biopharm, which refers to sales from the Watson-Marlow division to pharma and biotech, "is now expected to continue into 2024".

Looking ahead, the company said it expects its revenue group sales to be between flat and 4% higher for the year, when compared to 2022's pro-forma sales of GBP1.73 billion. Back in a May trading update, it predicted "double-digit sales growth for the group in 2023, representing mid-single-digit sales growth over 2022 pro-forma sales".

Savills slumped 8.7% as it reported a decline in first-half earnings.

The estate agent said pretax profit in the half-year ended June 30 plunged 88% to GBP6.0 million from GBP50.4 million 12 months earlier. Revenue declined 2.5% to GBP1.01 billion from GBP1.04 billion.

Chief Executive Mark Ridley said: "Savills has weathered both the inflationary cost conditions and reduced transaction volumes well, increasing market share and, supported by our strong balance sheet, continuing to undertake selective business development activities to further the group's long term growth strategy. We are seeing some positive signs in markets such as the UK and continued strength in certain Asia Pacific markets including Japan; in Continental Europe and mainland China we now expect reduced market volumes to continue through much of the year."

Elsewhere in London, Eco Atlantic jumped 12%, as it struck a deal to buy Tullow Oil's stake in a block in Guyana. Tullow was 1.2% higher.

Oil and gas explorer Eco will buy an additional 60% stake in the Orinduik block and will hold 75% as a result. TOQAP Guyana, a joint venture between TotalEnergies and QatarEnergy owns the remainder. Tullow no longer has a stake.

Eco Atlantic will pay USD700,000 to Tullow upfront, USD4 million in the event of commercial discovery and USD10 million upon the issue of a production licence from the government of Guyana. In addition, Tullow will have a royalty on future output.

Analysts at Peel Hunt commented: "We see this as a good deal for both parties, as it allows Tullow to continue to focus on its strategy of monetising its high-quality production assets with continued exposure to Guyana upside, while exploration-focused Eco has picked up a material stake in this high-potential licence for a relatively small upfront consideration. The deal also gives Eco additional optionality with regards bringing a new partner into the licence."

Stocks in New York are called to open higher on Thursday. Both the Dow Jones Industrial Average and S&P 500 are called up 0.5%, and the Nasdaq Composite 0.6% higher.

Beijing hit back on Thursday after the US restricted investments in Chinese technology.

US President Joe Biden hours earlier announced an executive order directing the Treasury Department to restrict certain US investments in China in sensitive high-tech sectors including semiconductors, quantum computing and artificial intelligence.

China's foreign ministry blasted the move as an attempt to "engage in anti-globalisation and de-sinicisation", warning that China would "resolutely safeguard its own rights and interests".

Analysts at UBS commented: "We expect tensions in the US-China bilateral relationship to remain elevated. A regime of increasing restrictions on technology transfer and capital flows between the two nations is likely to take hold and become a persistent irritant."

Gold was quoted at USD1,922.05 an ounce early Thursday afternoon, rising from USD1,916.66 on Wednesday. Brent oil was trading at USD87.38 a barrel, higher than USD86.92.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.